Evidence map›Paper›PMID 34422550›Full record

ArticleAnalytical cellular pathology (Amsterdam)2021

Molecular, Cytogenetic, and Hematological Analysis of Chronic Myeloid Leukemia Patients and Discovery of Two Novel Translocations.

Muhammad Asif, Abrar Hussain, Abdul Wali, Nazeer Ahmed, Irfan Ali, Zafar Iqbal, Muhammad Amir, Muhammad Shafiq, Mahmood Rasool

Open access · goldAbstract read
In one paragraph

Article in Analytical cellular pathology (Amsterdam), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. COVID-19 Impact on Chronic Myeloid Leukemia Patients.Journal of personalized medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Muhammad AsifDepartment of Biotechnology, BUITEMS, Quetta, Pakistan.ORCID https://orcid.org/0000-0003-4761-837X
Abrar HussainDepartment of Biotechnology, BUITEMS, Quetta, Pakistan.
Abdul WaliDepartment of Biotechnology, BUITEMS, Quetta, Pakistan.
Nazeer AhmedDepartment of Biotechnology, BUITEMS, Quetta, Pakistan.
Irfan AliCentre of Agricultural Biochemistry and Biotechnology, Agriculture University of Faisalabad, Pakistan.
Zafar IqbalClinical Laboratory Sciences Program, College of Applied Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences/KAIMRC/SSBMT, National Guard Health Affairs, King Abdulaziz Medical City, Al-Ahsa, Saudi Arabia.
Muhammad AmirDepartment of Biotechnology, BUITEMS, Quetta, Pakistan.
Muhammad ShafiqDepartment of Biotechnology, University of Sialkot, Pakistan.
Mahmood RasoolCenter of Excellence in Genomic Medicine Research, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID https://orcid.org/0000-0003-2997-5891
Balochistan University of Information Technology, Engineering and Management Sciences · PKKing Abdulaziz University · SAKing Saud bin Abdulaziz University for Health Sciences · SAUniversity of Faisalabad · PKUniversity of Sialkot

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myeloid leukemia (CML) is a disease of hematopoietic stem cells and is caused by the balanced translocations among the long arms of chromosomes 9 and 22, which are called the Philadelphia (Ph) chromosome. In this study, 131 CML patients were enrolled. Complete blood cell count was performed at the time of diagnosis for all the patients. Cytogenetic (karyotyping) examination using bone marrow samples was conducted on 76 CML patients for the confirmation of Ph-positive (9;22)(q34;q11) standard translocation, complex variant translocation, and additional chromosome abnormalities. FISH was performed on 38 patients for diagnostic purposes and on 39 patients for monitoring purposes. Twenty-two samples of CML patients were evaluated by reverse transcriptase PCR and real-time PCR for the patients who failed to respond against imatinib mesylate. In this study, 72 (54.96%) were males and 59 (45.03%) were females with a median age of 38.5 years. CBC values in the diagnosis process showed that 75 patients had high values of WBC being >100 × 10

Indexed as

Philadelphia ChromosomeTranslocation, GeneticAdolescentAdultAntineoplastic AgentsBiomarkers, TumorDrug SubstitutionFemaleHumansImatinib MesylateIn Situ Hybridization, FluorescenceKaryotypingLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedProtein Kinase InhibitorsAntineoplastic AgentsBiomarkers, TumorImatinib MesylatenilotinibProtein Kinase InhibitorsPyrimidines

Identifiers

PMID34422550
PMCPMC8378985
OpenAlexW3193843476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.